TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1709039
Drug: Spantide (substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spantide (substance P antagonist)
Study: 1709039
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no substance P antagonist)
Study: 25350851
Drug: RV144 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV144 vaccine
Study: 19672550
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 225 mcg/l lutein
Study: 19672550
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 120 mcg/l lutein
Study: 19672550
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 45 mcg/l lutein
Study: 19672550
Drug: Unfortified formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfortified formula (20 mcg/l lutein)
Study: 15261565
Drug: Cyclophosphamide 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 800 mg/m2 plus methylprednisolone 1 g IV (CY/MP)
Study: 11831539
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of amifostine (500 mg)
Study: 11831539
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of amifostine (500 mg)
Study: 11831539
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of amifostine (200 mg/m2)
Study: 10427933
Drug: Oral iodized
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iodized oil (OIO)
Study: 20143202
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific treatment)
Study: 2142699
Drug: L-tyrosine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine, 100 mg/kg/day
Study: 2142699
Drug: Imipramine, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine, 2.5 mg/kg/day
Study: 26424589
Drug: Gastrointestinal microbiome
Normalized name: GASTROINTESTINAL MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrointestinal microbiome modulator (GIMM)
Study: 16878429
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg t.i.d. for 16 weeks
Study: 12681885
Drug: Low-dose monophasic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monophasic oral contraceptives
Study: 12681885
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (women not using oral contraceptives)
Study: 22963506
Drug: Spironolactone 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 12.5 mg
Study: 24739800
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg
Study: 11129548
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg
Study: 8888663
Drug: Spironolactone 75
Normalized name: spironolactone 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 75 mg
Study: 6872169
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (5 to 30 mg)
Study: 28645983
Drug: slow-release Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release Mg hydroxide 30 mmol/day
Study: 18645513
Drug: Standard HIV/STD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HIV/STD Education (HE), one 60-minute session covering disease, testing, treatment, and prevention information.
Study: 16615668
Drug: Spirulina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina extract (250 mg) plus zinc (2 mg) twice daily for 16 weeks
Study: 7837405
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine 0.5 mg administered immediately after induction of spinal anesthesia (i.v. group)
Study: 7837405
Drug: Intramuscular atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular atropine 0.5 mg administered 30 min before induction of spinal anesthesia (i.m. group)
Study: 1472143
Drug: loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine 10 mg once daily
Study: 2904776
Drug: astemizole 10
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: astemizole 10 mg once daily
Study: 23147978
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (control)
Study: 24622724
Drug: Oral-Eze collection
Normalized name: ezetimibe Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-Eze collection device
Study: 10828633
Drug: Petrolatum-based formulation
Normalized name: PETROLATUM BASE
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum-based formulation delivered by the novel diaper
Study: 8102554
Drug: Vecuronium (V)
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium (V) 0.01 mg kg-1 BW followed by 0.04 mg kg-1 BW
Study: 8102554
Drug: Atracurium (A)
DrugBank: Atracurium (DB13295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atracurium (A) 0.05 mg kg-1 BW followed by 0.2 mg kg-1 BW
Study: 8102554
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of V and A in the 'priming'-technique
Study: 8706291
Drug: Oestradiol implants
Normalized name: Oestradiol Implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol implants
Study: 2880114
Drug: Oestradiol/testosterone implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol/testosterone implants
Study: 2880114
Drug: Placebo implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo implants
Study: 19051099
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride tablets (2 g) thrice daily for 4 days
Study: 17964349
Drug: Intravenous atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous atrial natriuretic peptide (0.025 microg/kg per min for 3 days)
Study: 17964349
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil (0.067 mg/kg as a bolus, followed by 1.67 microg/kg per min as a 24-h continuous infusion)
Study: 11244200
Drug: Unfractionated heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin, low‐molecular‐weight heparin, heparinoids
Study: 132330
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose therapy with phenytoin (4 doses of 4.4 to 6.3 mg/kg/dose given 8-hourly and then 6 mg/kg/day)
Study: 132330
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose therapy with phenytoin (5 to 9 mg/kg/day)
Study: 132330
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose therapy with phenytoin
Study: 26262828
Drug: Xtampza ER
Normalized name: Xtampza ER
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Xtampza ER (extended-release oxycodone)
Study: 19711465
Drug: Chemotherapy (BR.18)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (BR.18)
Study: 15994258
Drug: Creatine (creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (creatine monohydrate 5.7 g, glucose 35 g)
Study: 15994258
Drug: Placebo (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glucose polymer 40.7 g)
Study: 12865481
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P) injections
Study: 12586855
Drug: Weekly injections
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injections of testosterone (T; 100 mg/wk)
Study: 10227334
Drug: Zafirlukast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (20 mg BID)
Study: 7777307
Drug: Bandage contact
Normalized name: New-Skin Liquid Bandage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bandage contact lens with topical nonsteroidal anti-inflammatory drug (0.5% ketorolac tromethamine)
Study: 2108885
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg leuprorelin acetate depot
Study: 7006069
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (50 mg bid)
Study: 7006069
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg tid)
Study: 23963145
Drug: Chemoradiation (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation (4 courses of intravenous carboplatin on day 1 and oral vinorelbin on days 1 and 8 with 3-week intervals, plus radiotherapy 42 Gy/15 starting at the second chemotherapy course)
Study: 23963145
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (4 courses of intravenous carboplatin on day 1 and oral vinorelbin on days 1 and 8 with 3-week intervals)
Study: 18245761
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored geriatric treatment
Study: 16785188
Drug: Cisapride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (20 mg b.i.d.)
Study: 12865879
Drug: Vasogen's immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasogen's immune modulation therapy (IMT)
Study: 11053475
Drug: Ang II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ang II infusion (5 ng Ang II/kg per min)
Study: 11053475
Drug: Irbesartan premedication
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan premedication plus Ang II infusion (5 ng Ang II/kg per min)
Study: 8865704
Drug: 25g glucose
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25g glucose infusion in 30 minutes (group 1)
Study: 8865704
Drug: 50g glucose
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50g glucose infusion in 30 minutes (group 2)
Study: 8865704
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (25g and 50g glucose infusion)
Study: 6338091
Drug: Ultraviolet (UV)
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraviolet (UV) light treatment
Study: 30074217
Drug: Acupuncture cooperated
Normalized name: COOPER (AS CUPRIC OXIDE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture cooperated with sham rTMS treatment, 3 days per week for 4 weeks
Study: 26840902
Drug: Ketorolac NS
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac NS 31.5 mg
Study: 15928361
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus standard treatment
Study: 20033176
Drug: iomeprol 300
Normalized name: Iomeprol 300 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 300 mgI/ml
Study: 20033176
Drug: iopromide 300
Normalized name: IOPROMIDE 300mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide 300 mgI/ml
Study: 20033176
Drug: iopamidol 300
Normalized name: iopamidol 300 mg iodine/mL (61 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopamidol 300 mgI/ml
Study: 8793433
Drug: iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 300 mgI/ml
Study: 20033176
Drug: ioversol 320
Normalized name: IOVERSOL 320MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioversol 320 mgI/ml
Study: 20033176
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (first period of administration)
Study: 20033176
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (late period of administration)
Study: 18709675
Drug: Levodopa administration
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa administration after overnight withdrawal of dopaminergic medications.
Study: 18709675
Drug: Cold water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold water immersion test for PD patients 'off'-medication.
Study: 11249054
Drug: Epirubicin-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin-based chemotherapy
Study: 12037652
Drug: Saturated fat
Normalized name: Saturated fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated fat (SFA) from cream
Study: 2211266
Drug: Chemotherapy (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (3 cycles of 120 hr 5-FU infusion 1 g/m2/day plus Cis platin 100 mg/m2 on day 1 of each cycle)
Study: 2211266
Drug: Definitive local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definitive local treatment (surgery and post-operative radiation or radiation alone)
Study: 7407477
Drug: Cooked lentils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked lentils (50 g carbohydrate portion)
Study: 7407477
Drug: Cooked soya
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked soya beans (50 g carbohydrate portion)
Study: 23735726
Drug: Computer-administered minimal
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-administered minimal supportive intervention
Study: 21439397
Drug: Betamethasone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (12 mg/kg, two doses intramuscularly)
Study: 20374316
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg four times per day for 12 weeks)
Study: 20374316
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dosage and schedule as erythromycin)
Study: 17600085
Drug: Dexamethasone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (40 mg over 30 min, 16 h and 1 h before chemotherapy)
Study: 17600085
Drug: No dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No dexamethasone administration (control)
Study: 15140663
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of sodium phosphate solution
Study: 15140663
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate solution (both single and two doses)
Study: 3385217
Drug: C16:0 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: C16:0 and C18:0 PAFs (dose-dependent intradermal injection)
Study: 3385217
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of C16:0 and C18:0 PAFs (3:1 or 1:9 ratio)
Study: 21956255
Drug: Micafungin 100
Normalized name: micafungin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 100 mg/day
Study: 31066013
Drug: Fluconazole 100-200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100-200 mg/day (intravenous or oral)
Study: 23828452
Drug: 200-1000 ml
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200-1000 ml oral rehydration solution
Study: 20335146
Drug: Rosuvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin treatment for 12 months (n=40)
Study: 20335146
Drug: No rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rosuvastatin treatment (n=39)
Study: 12142560
Drug: High-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin-2 (HD IL-2)
Study: 15625368
Drug: IL-2 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 (5 MIU/m2 subcutaneously every 8 hours for three doses on day 1, then daily 5 days/week for 4 weeks) and interferon (5 MIU/m2 subcutaneously three times per week for 4 weeks)
Study: 15251318
Drug: Horse antilymphoblast
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse antilymphoblast globulin (ALG) at 10 mg/kg on alternate days (max 6 doses) with low-dose CsA at 8 mg/kg per day and prednisone at 0.25 mg/kg per day
Study: 15251318
Drug: CsA at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA at 15 mg/kg per day and prednisone at 0.5 mg/kg per day
Study: 1406835
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa combined with cyclophosphamide, vincristine, prednisone, and doxorubicin (treatment group)
Study: 23347693
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (MPH) 54 mg/day
Study: 23347693
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (MPH) 72 mg/day
Study: 23347693
Drug: OROS MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OROS MPH (54 mg and 72 mg)
Study: 16551903
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with subcutaneous normal saline injection
Study: 10447245
Drug: Iodized oil
Normalized name: ethiodized oil
DrugBank: Ethiodized oil (DB00965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized oil capsules containing 400 mg iodine (Group C)
Study: 7599866
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant human tumor necrosis factor-alpha (rhTNF alpha) 60 ng
Study: 2347435
Drug: 0.75 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g/kg ethanol
Study: 28768370
Drug: Nortriptyline 10
Normalized name: nortriptyline 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline 10 mg once daily
Study: 27920241
Drug: Mindfulness intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness intervention (monthly group sessions for 3 consecutive months)
Study: 24820465
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate at 2.4 mg/kg at 0, 12, and 24 hours, then daily
Study: 24820465
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine at a 20 mg/kg loading dose, then 10 mg/kg three times a day
Study: 1287904
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine
Study: 8594692
Drug: Quinine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine infusion
Study: 23682548
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO2) therapy, 60 daily sessions at 1.5 atm abs, 100% oxygen, 60 minutes each.
Study: 20228421
Drug: Quercetin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin supplementation (50, 100 or 150 mg/day) for two weeks in humans
Study: 20228421
Drug: Quercetin-enriched diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin-enriched diets (0.05 to 2 mg/g diet) for 6 weeks in mice
Study: 18824338
Drug: Zataria multiflora
Normalized name: Reynoutria multiflora root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zataria multiflora vaginal cream
Study: 18824338
Drug: metronidazole vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metronidazole vaginal gel
Study: 16390905
Drug: memantine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine (5-20 mg/day)
Study: 12584228
Drug: Peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2b plus fixed dosing of ribavirin
Study: 12584228
Drug: Peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2b plus weight based dosing of ribavirin
Study: 9890315
Drug: prednisolone, azathioprine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone, azathioprine, heparin‐warfarin, and dipyridamole for 2 yr (group 1)
Study: 9890315
Drug: heparin‐warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin‐warfarin and dipyridamole for 2 yr (group 2)
Study: 1835989
Drug: Lymphoblastoid or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoblastoid or recombinant alpha-interferon (2-6 months, ≥2 mega-units thrice weekly)
Study: 1835989
Drug: Lymphoblastoid or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoblastoid or recombinant alpha-interferon (9-18 months, variable dose)
Study: 30661255
Drug: cilofexor 100
Normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilofexor 100 mg
Study: 30661255
Drug: cilofexor 30
Normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilofexor 30 mg
Study: 27371977
Drug: Long-lasting insecticidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-lasting insecticidal nets plus topical repellent (picaridin KBR3023)
Study: 18307459
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDI) with glargine
Study: 12629071
Drug: Low-fixed dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fixed dose, 235 MBq
Study: 12629071
Drug: High-fixed dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fixed dose, 350 MBq
Study: 12629071
Drug: Low-adjusted dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-adjusted dose, 2.96 MBq (80 micro Ci)/g thyroid adjusted for 24 h radioiodine uptake